January 28, 2026

When Should Public Revenue-Generating Biotechs Pre-Announce?

For most early stage biotechs, revenue is a distant dream – a long way away, on the other side of both positive clinical data and regulatory approval. In the meantime, “revenue” lives as guesswork in both analyst models and in internal long-range forecasts.

Some biotechs do go on to generate real, recurring revenue, however. In doing so, this typically means that management and shareholders forgo an outright sale of the company, in favor of going it alone and becoming commercial stage. Which, of course, is accompanied by the expectation that the company will host quarterly earnings calls.

When this happens, a biotech’s stock trades less on the prospects of its development pipeline (which might by then be non-existent), and more on its hits or misses of consensus’ quarterly revenue.

For this reason, some biotechs will occasionally choose to pre-announce quarterly revenue, with a view to managing (or resetting) both investor expectations and covering analysts’ financial models.

While pre-announcements are common in other industries, in biotech, they are rare. Done well, they can build credibility. Done poorly, they can create confusion, volatility, and unnecessary scrutiny.

First principles: why pre-announce at all?

Pre-announcements typically occur for one reason: to manage expectations when reported results are likely to diverge meaningfully from consensus.

(Note: companies will also sometimes pre-announce ahead of the J.P. Morgan Healthcare Conference, or on rare occasions before another event, thus enabling them to talk about their results ahead of their official quarterly announcement).

In this regard, the primary question we get from clients is – how should we determine what is “meaningful?” In response, we articulate that our general rule of thumb is a 10% divergence from company guidance (not consensus).

Note here that “meaningful” is not the same as material. Some pre-announcements fall into the category of being required because they are part of a larger material event (acquisition or divestiture), which necessitates its own disclosure. In that case, a pre-announcement would likely appear as part of a larger release.

Importantly, the divergence we’re talking about can cut both ways. Revenue may be materially ahead of expectations due to faster uptake, a large one-time order, or a favorable reimbursement event. Or it may fall short because of shipment timing, customer concentration, or temporary/unforeseen operational issues.

The latter, alas, tends to be the more frequently pre-announced news.

If the difference between expectations and reality is not meaningful, biotechs should do nothing. Over-communicating small beats or misses trains investors to overreact – and invites questions you don’t want to answer.

The case for pre-announcing upside.

Positive pre-announcements make sense when revenue upside is both material and either durable or part of a large one-time event.

Examples include:

• A step-change in demand that alters forward guidance.
• A contract win that meaningfully extends visibility.
• Commercial traction that validates a debated launch thesis.
• A tuck-in acquisition that impacts revenue and/or margins.

In these cases, waiting until an earnings call could be counterproductive. Investors will eventually discover the upside, but the market might spend weeks speculating in the meantime. A short, factual pre-announcement can anchor expectations and reduce rumor-driven volatility.

Restraint is key. Pre-announcements should be concise, factual, and free of promotional language. If yours sounds like a victory lap, you’re probably making a mistake.

The case for pre-announcing downside.

Downside pre-announcements are more common but also more important.

If revenue is likely to miss expectations in a way that could surprise the market, silence is rarely the right answer. Why? Because investors are far more forgiving of bad news delivered early than bad news delivered late.

Common reasons for pre-announcing disappointing figures include:

• Customer ordering delays.
• Concentration risk from a small number of accounts.
• Timing issues around milestone payments or shipments.
• Operational challenges (strike, fire, supply chain disruption).

Here, the objective of pre-announcing is not to soften the blow, but to preserve management’s credibility (and more widely trust). Pre-announcing allows you the opportunity to frame the issue accurately and explain whether it is transient or structural.

What biotechs get wrong.

1. The most frequent error is treating revenue like data. While clinical data is episodic, revenue is a continuously reported metric. If you start pre-announcing every quarterly fluctuation, you will create an expectation that you will always do so, and that is a dangerous precedent.
2. Another mistake is pre-announcing without context. Revenue numbers divorced from guidance, margins, or durability raise more questions than they answer. As such, if you pre-announce, be prepared to explain why it matters.

Timing and mechanics.

Pre-announcements should occur as soon as management has high confidence in the outcome (not to mention internal alignment). In most cases, a simple press release is usually sufficient with no deck, no call, and most importantly, no theatrics.

Analysts and investors will want to talk to you once the news is made public, so be prepared to either triage inbound inquiries with a prepared statement (since you will likely be in a quiet period ahead of the actual reporting date) or determine in advance that you will proactively arrange calls with covering analysts with a well-defined Q&A in hand.